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j ourna l homepage: www.e lsev ie r .com/ locate /goreThe role of cisplatin alternative regimens
with radiotherapy in cervical cancercancer. Ryu et al. demonstrated that triweekly cisplatin 75 mg/m2In 1983, a double blind randomized control trial (RCT) demonstrated
the beneﬁt of radiosensitization with chemotherapy during radiothera-
py on advance stage cervical cancer Piver et al., 1983. Sixteen years and
approximately 127,600 cases of cervical cancer in theUnited States later,
four RCTs showed chemotherapy to be the preferred option as a
radiosensitizer concurrently with radiotherapy for advance cervical cancer
(Keys et al., 1999; Morris et al., 1999; Rose et al., 1999; Whitney et al.,
1999). In the same year, the National Cancer Institute (NCI)made a clinical
announcement stating that “strong consideration shouldbegiven to adding
concurrent chemotherapy to radiation therapy in the treatment of invasive
cervical cancer.” However it remained to be determined whether single
agent cisplatin was the optimal choice (National Cancer Institute, 1999).
In fact, according to theNCI, “It is not possible from these trials to conclude
which cisplatin-based regimen is the optimal one.”
Over the past decade, several RCTs were conducted comparing
cisplatin-based polychemotherapy versus cisplatin-only with radio-
therapy. Petrelli et al. recently published a meta-analysis comparing
standard concurrent weekly cisplatin and pelvic irradiation with other
platinum containing regimens (Petrelli et al., 2014). Four prospective
randomized trials and four retrospective studieswere eligible, including
approximately 1500 cervical cancer patients ranging from stage I to IVA.
The authors concluded that platinum-based doublet therapy with
concurrent irradiation is the “preferred treatment” and “potentially
the best regimen” for stage IB-IVA cervical cancer, with enhanced
locoregional control and minimally increased toxicity compared to the
traditional single agent weekly cisplatin. They even concluded that
there was a suggestion of improved progression free and overall survival
for doublet therapy.
The result of this meta-analysis shed a light on how standard treat-
ment for advance stage cervical cancer can be improved by adding
other chemotherapies to single agent cisplatin regimens. However, the
authors did admit that there are limitations to their study and in those
included in the meta-analysis. For instance, when looking closer at
the four RCTs, two trials (Duenas-Gonzalez et al., 2005; Pu et al.,
2013) included early and advance stage cervical cancer patients. The
heterogeneity among the populations studied, limits the application of
the study results to any speciﬁc subpopulations. The meta-analysis ob-
served an increase in gastrointestinal toxicities, thrombocytopenia,
and neutropenia as expected with the usage of cisplatin doublets, but
concluded that toxicity is “minimally increased”. This was also seen
according to a RCT published by Roy et al. (2011). In this study however,
the cisplatin gemcitabinedoubletwasmuchmore dose intense compar-
ing to theweekly cisplatin group. Despite anunequal dose intensity, and
even though 60% of the doublet group could not complete therapy on
schedule, the doublet outcomes were sufﬁciently favorable to suggest
further studies of doublet therapy.
Aside from adding another agent to theweekly cisplatin chemother-
apy, two additional RCTs from Ryu et al. and Nagy et al. also showed
that weekly cisplatin is not the only choice for advance stage cervicalhttp://dx.doi.org/10.1016/j.gore.2014.10.006
2352-5789/© 2014 The Authors. Published by Elsevier Inc. This is an open access article underevery 21 days, concurrent with radiotherapy is more effective with an
increase in overall 5 year survival of 18%, and a reduction in the risk of
death by 62.5% (HR 0.375, p= 0.03). It was also overall less toxic than
weekly cisplatin treatment. For instance, grade 3–4 neutropenia was
approximately half of that seen with the weekly regimen (Ryu et al.,
2011).
The results of Nagy et al. were similar, showing that daily cisplatin,
20 mg/m2 for 5 days every three weeks has a superior ﬁve-year local
relapse-free survival (p b 0.01), lesser toxicity, and a similar 5-year
survival rate compared with the standard weekly cisplatin treatment
(Nagy et al., 2012).
Based on the meta-analysis of Petrelli et al. and the 8 RCTs compar-
ing single agent weekly cisplatin to other regimens (see Table 1), it is
reasonable to conclude thatweekly cisplatin is no longer the only option
for chemosensitization with radiotherapy for locally advanced cervical
cancer.We hope that amore comprehensivemeta-analysis in the future
will include some of these other trials that show a trend toward beneﬁt
for alternatives toweekly platinum. For instance, Pu et al. showed an in-
triguing trend toward improved 5 year local recurrence (79.3% versus
69.3%, p= 0.061) and overall survival (82.8% versus 74.3%, p= 0.098)
Pu et al., 2013. It is likely that had a one tail test been used, the results
would have been statistically signiﬁcant. These slightly under powered
studies are ideally suited for inclusion in meta-analyses.
Over more than 30 years, chemosensitization for cervical cancer has
seen little change. The time between an early report of beneﬁt (circa
1984) to widespread adoption (1999) of chemosensitization, may
have cost the lives of many women who could have beneﬁted from
the improvement in overall survival. We are again at a pivotal time
when alternatives to a comfortable standard are being challenged.
Given the widespread large number of cases of new cervical cancer in
the world today, any delay in adopting new advances may be costly.
Further studies are warranted to determine the optimal doublet
or other alternatives to single agent weekly cisplatin. Further studies
are not needed to justify continued use of single agent cisplatin. Let's
not relive 1984.
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Table 1
Eight randomized control trial comparing polychemotherapy and weekly cisplatinadjunct to pelvic radiotherapy.
Author, year Patient no.
experimental/control
arms
Stage Median
follow-up
(months)
Chemotherapy schedules experimental/control arms CT completion
experimental/control
arms
Surgery included as
part of treatment
plan
Outcomes (experimental/control arms)
Disease status OS
Rose, 2007 (long term
follow-up of 1999
study)
173 IIB–IVB 106 50 mg/m2 CDDP IV on D1,D29 + 4 g/m2 5-FU ci
96 hrs on D1,D29 + 2 g HU PO twice weekly at wks
1–6
CDDP 80.9%, 5-FU
79.2%, HU 19.7%
Nil PFS: 43% at 10 53% at 10
176 Conventional CDDP 49.4% PFS: 46% at 10 53% at 10
Duenas-Gonzalez, 2011 43 IB2–IIB 20 6wk-40 mg CDDP + 125 mg Gem 63% 100% CR pathologica. 77.5% p = 0.0201
40 Conventional CDDP 82% CR pathologic: 55%
Kim, 2008 78 IIB–IVA 39 20 mg/m2/d CDDP + 1000 mg/m2/d 5FU ci x 5 days,
q28d x3 cycles
65% Nil PFS: 67% at 4 70% at 4
77 6wk-30 mg CDDP 73% PFS 66% at 4 67% at 4
Duenas-Gonzalez, 2011 259 IIB-IVA 46.9 6wk-40 mg CDDP + 125 mg Gem, with adjuvant
50 mg CDDP (D1) +1000 mg Gem (D1,8) x2 cycles
Median: 5 cycles
Adjuvant: 76.5%
Nil PFS:74.4%
at 3
HR = 0.68 (95% CI,
0.49-0.95)
p = 0.029
N/A HR = 0.68 (95% CI,
0.49–0.95),
p = 0.0224256 Conventional CDDP Median: 6 cycles PFS:65.0%
at 3
69.1% at
3
Ryu, 2011 53 IIB–IVA 60 Triweekly 75 mg CDDP x3 cycles 92.5% Nil 5 recurrence rate: 24.5% 88.7% at
5
HR 0.375 (95% CI,
0.154–0.914)
p = 0.0351 Conventional CDDP 86.3% 5 recurrence rate: 29.4% 66.5% at
5
Nagy, 2012 164 IIB–IIIB 68.1 20 mg/m2/d CDDP x5 days, q21d x2 cycles Op: 78% non-op: 80% 59% DFS: 73%
at 5
p = 0.09 78% at
5
p = 0.14
162 Conventional CDDP Op: 83% non-op: 42% 67% DFS: 69%
at 5
72% at
5
Pu,2013 145 IB–IIA 60 5wk-30 mg CDDP + 30 mg DOC 79.3% 100% RFS:79.3%
at 5
HR 0.64 (95 % CI,
0.40-1.03)
p = 0.061
82.8% at
5
HR 0.65 (95 % CI,
0.39–1.09) p = 0.098
140 Conventional CDDP 75% RFS:69.3%
at 5
74.3% at
5
Roy,2014 25 IIB–IIIB 17 6wk-40 mg CDDP+125 mg Gem “10 patients
completed within 10
wks.”
Nil DFS: 83%
at 21 mos
p = 0.69 100% at
21 mos
p = 0.14
25 21 Conventional CDDP “most completed
within 9 wks”
DFS: 73%
at 21 mos
84.5% at
21 mos
5-FU: 5-ﬂuorouracil; 6wk-40 mg CDDP+125 mg Gem: 6 course of weekly 40 mg/m2 cisplatin with 125 mg/m2 gemcitabine; BT: brachytherapy; CDDP: cisplatin; ci: continue infusion; Conventional CDDP: 5–6 course of weekly cisplatin at 40 mg/m2; CR
pathologic: complete pathologic response rate; CT: chemotherapy; D1,D8: day 1, day 8; DFS: disease free survival; Gem: gemcitabine; HDR: high dose rate; HU: hydroxyurea; IV: intravenous; mos: months; N/A: not applicable; Op: operation; OS: overall
survival; PFS: progression free survival; PO: orally; q28d: every 28 days; RFS: recurrence free survival; wks: weeks; DOC: docetaxel; yr: year.
a Those with no evidence of tumor cells or residual microscopic disease in the absence of any or intermediate- or high-risk factors for recurrence (near-complete).
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